A B S T R A C T Human malaria parasites (Plasmodium falciparum) grown in continuous erythrocyte culture utilize hypoxanthine for synthesis of both guanosine and adenosine nucleotides. Unlike the mature human erythrocyte, the malaria parasite depends on a constant supply of guanylates, primarily for synthesis of nucleic acids. This parasite specific requirement for guanylates led us to predict that a block in the hypoxanthine to quanosine monophosphate pathway would be selectively lethal to the parasite. Bredinin (4 -carbamoyl-1 -,B-D -ribofuranyosyl -imidazolium -5-olate) inhibited the synthesis of guanosine monophosphate from inosine monophosphate by parasitized erythrocytes. This block in guanylate synthesis was fatal to both a drug-sensitive (FCR-3) and a drug-resistant (VNS) strain of the malaria parasite at a bredinin concentration of 50 MM, arresting growth of the parasite at the trophozoite stage of development. These studies emphasize the essential role of guanylates and their synthesis from hypoxanthine in the metabolism of malaria parasite. They further suggest that bredinin or similar agents that selectively interfere with parasite guanylate metabolism may have potential for antimalarial chemotherapy.
INTRODUCTION
Truly rational approaches to antimalarial chemotherapy have been hampered by a lack of basic biochemical understanding of host-parasite relationships in human malaria infection. A major obstacle in the study of such host-parasite relationships was the lack of an effective in vitro culture system for human Plasmodia species. However, this problem was overcome with the Dr. Webster Received for publication 11 August 1981 and in revised form 22 April 1982. development of in vitro culture techniques (1, 2) that permit continuous growth of the malaria parasite in human erythrocytes (RBC). 1 We have used malaria culture techniques to study purine metabolism during the intraerythrocytic (IE) growth cycle of Plasmodium falciparum (malignant tertian malaria). We have concentrated on purine metabolism in our studies because of its importance to both the host RBC (3) and malaria parasite when studied in animal models (4) (5) (6) . Identification of differences in host-parasite purine metabolism could present appropriate targets for design of new antimalarial chemotherapy.
Purine nucleotides are essential to both the RBC and parasite for energy metabolism, as enzyme cofactors and as intermediary metabolic regulators. However, only the parasite requires purine nucleotides for synthesis of nucleic acids (DNA and RNA), proteins, and folates (7, 8) . We have paid particular attention to pathways for guanylate metabolism in malaria-infected RBC. A supply of guanine nucleotides appears to be a unique requirement of the parasite in contrast to the mature RBC where no established role for these compounds exists (9) .
Using novel chromatographic techniques to study purine metabolism in malaria infected RBC in vitro, we have identified the major metabolic pathways used by IE P. falciparum to synthesize both guanosine and adenosine nucleotides from the precursor purine base, hypoxanthine (10) (12, 13) and used in human volunteer studies (14) .
Experimental assays were done as follows. Ribonucleosides and bases were found predominantly in the ECM, whereas ribonucleotides were almost all found intracellularly. Extraction with PCA was found to give good recoveries (294%, using radiolabeled standards) of all ribonucleotides reported. Deoxyribonucleotides, for which PCA extraction is not particularly efficient, were not reported.
Determination of radioactivity incorporated into nucleic acids was done by alkali solubilization of the acid-insoluble material formed during PCA-extraction of PRBC. An aliquot of solubilized pellet was counted by liquid scintillation counting. Protosol (New England Nuclear) was used to dis-solve the twice-acid-washed cell pellet. This technique measures total nucleic acids and, therefore, provides an estimate of label incorporated into both DNA and RNA.
Quantitation of purine compounds by simultaneous UVradioactivity HPLC. Purines were assayed using an HPLC system that simultaneously measured the concentration and radioactivity of separated components (15) . Basically, the HPLC system consisted of the following: a model 3500B HPLC (Spectra-Physics Inc., Mountain View, CA) fitted with a solvent programmer and sample injector value; model 152 dual wavelength (254 and 280 nm) detector with 20 j1 analytical flow cell (Altex Company, Tarrington, CT) connected to a System I Computing Integrator (Spectra-Physics) and strip-chart recorder (Hewlett-Packard Co., Palo Alto, CA); a FLO-ONE radioactivity flow detector with a 500-iJ flow cell (Radiomatic Instruments & Chemical Co.). The radioactivity flow detector was connected in series with the UV-detector (column effluent passed first through the UV flow cell, then through the radioactivity flow cell). The radioactivity detector unit mixed the column effluent with scintillation fluid (predetermined ratio) for counting in the flow cell.
Purine nucleosides and bases were separated by reversedphase HPLC using an Ultrasphere-5 ODS column (Altex Company). Purine nucleotides were separated by anion-exchange HPLC with a Partisil-10 SAX microparticulate column (Whatman, Inc., Chemical Separation Div., Clifton, NJ).
The neutralized PCA extracts were thawed and injected directly onto the HPLC column using a valve injector (Valco Engineering Corp., Springfield, NJ) fitted with an 123-ul loop. Samples prepared in this manner contained sufficient amounts of ribonucleotides for detection and accurate quantitation. Deoxyribonucleotides were separated from their corresponding ribonucleotides by both the reversed-phase and anion-exchange HPLC techniques. Deoxyribonucleotide forms were found to elute distinctly just after the corresponding ribonucleotide form. These separation profiles were confirmed using commercial (Sigma Chemical Co.) purine standards. Deoxyribonucleotides were not, however, detected routinely in sample extracts, due to their low intrinsic pool levels and the noted questionable recovery with PCA extraction.
Concentrations were determined by an external standard method based on absorbance (254 nm) using solutions of purine standards of known purity. For radioactivity measurements, peak areas were machine-integrated and recorded as total counts per radioactivity peak.
Microtiter assay. Evaluation of bredinin's antimalarial activity in terms of dose response was done by microtitration techniques essentially as described by Desjardins and colleagues (14) . Microtiter 
RESULTS
Effect of bredinin on purine nucleotide synthesis. Fig. 2 (a-c) (Fig. 2b) . Adenylate synthesis from IMP, which occurred only in malariainfected RBC, also accounted for the appearance of radioactivity in pyridine nucleotides (radioactivity peak 1 was NAD, Fig. lb) . In the presence of bredinin (50 gM) there was decreased incorporation of ['4C]hypoxanthine into the guanosine nucleotides of PRBC ( Fig. lc; compare radioactivity peaks 5 and 7, Figs. lb and lc). Table I shows the quantitative results obtained using individual cultures (triplicates) to which both the isotope and drug were added following the medium change and redistribution of the PRBC volume (unit flask assay). The parasitemia (percent infected RBC and distribution of IE parasite growth stages) for each culture was equivalent at the start of the experiment. The data were obtained by integration of chromatographic peaks of the HPLC eluation profiles. In the presence of bredinin (50 uM) there was a decrease in the incorporation (85%, P < 0.001) of ['4C]hypoxanthine into guanylates (GDP, GTP, EG) of PRBC, compared with untreated PRBC, after 24-h incubation in the presence of labeled hypoxanthine. There was also a decrease in GDP (25%, P < 0.01) and GTP (39%, P < 0.001) pool levels in the infected RBC cultures. Production of IMP from hypoxanthine was not affected by bredinin, indicating a block in the synthesis of GMP from IMP. Hypoxanthine levels were found to be higher-in extracts of ECM from bredinintreated PRBC compared with untreated PRBC (11±1 vs. 7±1 nmol/ml, P < 0.02; and 4,087±38 vs. 2,910±138 as regards radioactivity per chromatographic peak). (Table I ). The reduced amount of radioactivity in adenylates (IA) noted in the bredinin-treated PRBC was thought to reflect primarily a decreased availability of GTP required in the synthesis of adenylosuccinate from IMP. The increased levels of AMP in treated PRBC was most likely due to increased catabolism of ATP.
That the block in guanylate synthesis produced by bredinin affected parasite's nucleic acid synthesis was evident from comparison of incorporated radioactivity into the acid-insoluble residue (pellets) following PCA extraction. In this series of experiments bredinin (50 FIGURE 2 (a-c) Purine nucleotide profiles obtained by simultaneous UV-radioactivity HPLC. Neutralized PCA extracts prepared from malaria/RBC cultures and injected onto an anionexchange column for separation of purine nucleotides by the HPLC procedure described in the text. This procedure allows the simultaneous quantitation of both concentration (254 nm) and radioactivity of separated purine components. Absorbance is traced on a linear scale, whereas the radioactivity trace is on a logarithmic scale. Peaks were computer integrated. (7) 341±32 (dpm±SEM, n = 3 P < 0.05). This reflects a 28% decrease of incorporated label into nucleic acids by bredinin-treated PRBC relative to untreated PRBC during a 24-h incubation period.
The experiments reported thus far all involved the FCR-3 strain of P. falciparum that was chloroquine sensitive. It was of interest to examine the effect of bredinin on a chloroquine-resistant malaria parasite, the VNS strain. A unit flask assay, similar to that reported above with the FCR-3 strain, was done using the VNS strain. Cultures for both bredinin-treated (50 ,uM) and untreated PRBC were set up in quadruplicate with extracts of individual cultures analyzed by HPLC as described under Methods. A decrease in both concentration and incorporated radioactivity of guanylates was observed (EG, 52±6 nmol/ml RBC vs. 88±9 nmol/ml RBC, 41% decrease, P < 0.005; ZG 128±37 radioactivity/peak vs. 800±88 radioactivity/peak, 84% decrease, P < 0.005); for bredinin-treated PRBC compared with untreated PRBC. There were no major observed differences in the overall purine metabolism of labeled [14C] hypoxanthine noted between the two strains of P. falciparum.
Although the results from the unit flasks assay approach demonstrate that bredinin interferes with the synthesis of GMP from IMP by malaria PRBC, it does not establish which enzyme in this pathway, IMP dehydrogenase or GMP synthetase, was inhibited. As noted above for conditions of the unit flasks assay, levels of XMP and GMP were not detected. Presumably, this was due to the relatively small numbers of erythrocytes (Hct 12) and a sufficiently rapid turnover of these nucleotide monophosphates to preclude their accumulation. Nonetheless, if bredinin did interfere with GMP synthetase, some accumulation of XMP would be anticipated, particularly in view of the absence of a xanthine oxidase in human RBC and the fact that no build-up of labeled uric acid during the culture period was observed in chromatograms of ECM from bredinin-treated PRBC.
As a means of evaluating the levels of GMP and XMP during parasite growth, a pooled flask assay was used. In this way it was possible to obtain Hct -30. Note that in this assay the inhibitor and isotope were added after the second medium change (higher starting parasitemia) and then incubation continued for 3 h. The parasitemias were equivalent in both treated and untreated cultures, due to the pooling and redistribution done at the medium change. There was no significant change in the parasitemia of any cultures during the 3-h incubation (5.8±0.8% PRBC; n = 3). Table II shows that the amount of radioactivity from ['4C]hypoxanthine incorporated into both XMP and GMP was sharply decreased in bredinin-treated PRBC as compared with untreated PRBC. This effect of bredinin was particularly evident when the specific activities for GMP and XMP were compared for treated vs. untreated PRBC (Table II) . Although the differences in actual concentration (nanomoles per milliliter RBC of GMP and XMP) were small, the sharply decreased specific activities for these mononucleotides in bredinin-treated PRBC indicates a considerable reduction in the synthesis of new XMP and GMP during the 3-h incubation period. These data suggest, therefore, that bredinin acts on IMP dehydrogenase.
Rescue of bredinin-treated PRBC by exogenous GMP. Table III shows that addition of GMP (50 gM) to bredinin-treated (50 FM) PRBC reverses inhibition as measured both by incorporation of [3H]isoleucine into protein and parasite growth. There was significant (P < 0.001) incorporation of isoleucine into PRBC accompanied by parasite growth when bredinin-treated PRBC were incubated in the presence of equimolar GMP. Lower concentrations of GMP were less effective. Reversal of the inhibition of GMP synthesis from hypoxanthine in the presence of exogenously added GMP was not noted (observation based on unit flask assay). The GMP provides an alternative source of purine base for synthesis of guanylates by the parasite (viz: G -i GMP -i GDP -i GTP). There were no detectable levels of guanine or guanosine in the ECM under the conditions of culture used for these studies. These data indicate both that hypoxanthine is the source of parasite GMP and that guanylates are essential to parasite growth.
Use of the microtiter assay to confirm the antimalarial activity of bredinin. To assess the effects of bredinin on malaria parasite survival and growth in vitro, a microtiter assay technique was used. Uptake of [3H]hypoxanthine into precipitable material (nucleic acids) served as a biochemical indicator of parasite growth and microscopic examination of Giemsa-stained smears prepared from each microtiter well permitted evaluation of parasite maturation and proliferation. Fig. 3 shows the effect of varying concentrations of (8, 17) . The loss of GTP would thus affect two parasite growth essential areas of metabolism-nucleic acids (DNA/RNA) and folates. These studies demonstrate how basic biochemical information on intermediary metabolic pathways obtained through the use of human malaria culture techniques can lead directly to the identification of potential antimalarial agents. Through use of continuous RBC culture for P. falciparum (the major human malaria pathogen) it was possible to identify clearly the metabolic fate of the purine base, hypoxanthine. The simplicity of the culture system (RBC and malaria parasite) allowed detection of the purine pathways through which hypoxanthine was metabolized. Similarly, the control cultures permitted ready distinction of differences in metabolic pathways in unparasitized RBC as compared with malaria-infected RBC.
The identification of a metabolic pathway from hypoxanthine to guanosine nucleotides in PRBC, even though present to a limited extent in unparasitized RBC, made this pathway a logical selection as a chemotherapeutic target, based on the parasite's requirement for nucleic acid synthesis. The extensive literature on chemical agents examined for potential use in cancer chemotherapy made it possible to quickly identify compounds, like bredinin, known to affect guanylate metabolism in various experimental systems. A number of compounds other than bredinin have been shown to inhibit growth of tumor cells in tissue culture by interfering with synthesis of GMP from IMP: virazole, mycophenolic acid, psicofuranine, and decoyinine (18) . We are presently examining several of these agents for antimalarial properties.
Although the antimalarial action of bredinin, demonstrated here in vitro, is as yet untested in vivo, the biochemical study of human malaria-infected RBC in vitro as described in this study, offers a rational approach to the discovery of potential metabolic targets for directed chemotherapy as well as the identification of new classes of candidate antimalarial drugs.
